What is your preferred choice and timing of systemic therapy in a patient with high risk oligometastatic prostate cancer undergoing metastasis directed therapy to all sites of disease, including the prostate?

Answer from: Medical Oncologist at Community Practice

Metastasis-directed therapy (MDT) is an option for patients with oligometastatic prostate cancer who wish to delay initiation of ADT, based on STOMP (Decaestecker et al., PMID: 25223986) and ORIOLE (Phillips et al., PMID: 32215577) trials. In the STOMP study, 61% of patients (3 or fewer metastases) ...

Comments

Radiation Oncologist at Providence St Mary Cancer Center
Thank you for your summary of data regarding MDT. ...

Radiation Oncologist at South County Health Radiation Therapy
Do you offer elective pelvic RT as well?

Please select the option that best describes you:

What is your preferred choice and timing of systemic therapy in a patient with high risk oligometastatic prostate cancer undergoing metastasis directed therapy to all sites of disease, including the prostate?

Related Questions